From the weekly letter · 2 November 2026

Why cover this story this week?

A hemorrhagic fever virus depends on host entry receptors

A preprint on Crimean-Congo hemorrhagic fever virus identifies host-cell molecules that may offer targets for antiviral development. The researchers found that phosphatidylserine receptors, including AXL, TIM-1 and TIM-4, support infection in cell lines and liver-derived primary cultures. Small molecules and antibodies directed against these receptors greatly reduced infection in culture.

Genetic experiments extended the finding beyond a laboratory entry assay. Removing individual receptor genes partially protected mice against lethal viral challenge, while mice lacking a pair of receptors were completely protected, with viral and inflammatory measurements reduced to baseline. This makes the receptors candidates for intervention against disease, not merely clues to how the virus enters cells. However, protection from inherited receptor loss does not establish that a drug given after infection would achieve the same result.

Editorial context written by AI from abstracts, not independent scientific validation. The kit and its verified quotes rely on the source paper, not on this letter.

Read the full letter →

Talk about a paper in public without overstating it: yours, one you are asked to comment on, or one you write about as a journalist.

  • Your paper: a draft release for your press office, the questions journalists will ask with what the paper lets you answer, the likely misreadings, a lay summary and a short thread.
  • Asked to comment: what the paper shows and does not, its strengths and weaknesses with their passages, and what would settle its main claim.
  • Writing about it as a journalist: reporting angles, the wording to check before publication, and the questions to ask the authors.
  • For everyone: findings with their passages checked word for word, the novelty set against the closest earlier papers, a hype check, figures with their credit, and researchers for an outside view who have not signed with the authors.

Discover Premium+ See an example kit